Braidwell LP Buys 250,800 Shares of Globus Medical, Inc. $GMED

Braidwell LP boosted its position in shares of Globus Medical, Inc. (NYSE:GMED) by 101.5% during the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 498,000 shares of the medical device company’s stock after buying an additional 250,800 shares during the quarter. Braidwell LP’s holdings in Globus Medical were worth $28,520,000 as of its most recent SEC filing.

A number of other hedge funds have also recently bought and sold shares of the company. EverSource Wealth Advisors LLC increased its stake in shares of Globus Medical by 74.3% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 462 shares of the medical device company’s stock valued at $27,000 after buying an additional 197 shares during the period. Advisors Asset Management Inc. bought a new stake in shares of Globus Medical during the second quarter worth $28,000. First Horizon Corp acquired a new position in shares of Globus Medical during the third quarter valued at $31,000. Parallel Advisors LLC lifted its stake in shares of Globus Medical by 45.1% during the third quarter. Parallel Advisors LLC now owns 557 shares of the medical device company’s stock valued at $32,000 after acquiring an additional 173 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. bought a new position in Globus Medical in the third quarter valued at about $36,000. 95.16% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of brokerages recently commented on GMED. Citigroup reiterated a “market perform” rating on shares of Globus Medical in a research report on Thursday, January 8th. Truist Financial set a $115.00 target price on shares of Globus Medical in a research report on Wednesday, February 25th. Needham & Company LLC raised their target price on shares of Globus Medical from $112.00 to $114.00 and gave the company a “buy” rating in a research note on Wednesday, February 25th. BTIG Research reiterated a “neutral” rating on shares of Globus Medical in a research report on Tuesday, December 30th. Finally, Wall Street Zen raised shares of Globus Medical from a “buy” rating to a “strong-buy” rating in a research note on Saturday, January 3rd. Two analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and five have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $104.36.

Globus Medical Price Performance

Globus Medical stock opened at $84.81 on Friday. The company’s 50 day simple moving average is $90.71 and its 200 day simple moving average is $78.37. Globus Medical, Inc. has a fifty-two week low of $51.79 and a fifty-two week high of $101.40. The firm has a market capitalization of $11.47 billion, a price-to-earnings ratio of 21.52, a PEG ratio of 1.99 and a beta of 1.05.

Globus Medical (NYSE:GMED) last issued its quarterly earnings data on Tuesday, February 24th. The medical device company reported $1.28 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.06 by $0.22. Globus Medical had a net margin of 18.30% and a return on equity of 12.57%. The firm had revenue of $826.42 million during the quarter, compared to analysts’ expectations of $803.29 million. During the same quarter in the previous year, the company earned $0.84 earnings per share. The business’s revenue for the quarter was up 25.7% on a year-over-year basis. As a group, analysts predict that Globus Medical, Inc. will post 3.44 EPS for the current fiscal year.

Globus Medical News Roundup

Here are the key news stories impacting Globus Medical this week:

• Positive Sentiment: Zacks Research sharply raised EPS forecasts across multiple quarters and years and maintained a “Strong‑Buy” rating — the firm bumped Q1, Q2 and Q3 2027 estimates and raised FY2026 and FY2027 outlooks (FY2027 to $4.66). Improved analyst earnings trajectories support higher forward valuations and raise the bar for future guidance. Zacks Research Raises Earnings Estimates for Globus Medical
• Positive Sentiment: Brokerage consensus sits at an average “Moderate Buy” rating — this aggregate analyst view suggests continued institutional support and can attract momentum buying as earnings estimates move higher. Globus Medical Given Average Rating of “Moderate Buy” by Brokerages
• Neutral Sentiment: Technical/valuation context is mixed — GMED is trading above its 200‑day moving average (longer‑term support) but below its 50‑day average (shorter‑term momentum). The stock still trades at a mid‑teens to low‑20s P/E on forward estimates, so further upside may depend on continued estimate upgrades or stronger organic revenue/ margin beats. MarketBeat GMED Page

Insider Activity

In related news, CFO Kyle Kline sold 3,594 shares of the firm’s stock in a transaction on Thursday, January 8th. The stock was sold at an average price of $101.10, for a total transaction of $363,353.40. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, EVP Kelly Huller sold 20,000 shares of Globus Medical stock in a transaction dated Wednesday, February 25th. The stock was sold at an average price of $94.50, for a total value of $1,890,000.00. The disclosure for this sale is available in the SEC filing. Insiders sold 35,594 shares of company stock valued at $3,332,253 in the last quarter. Company insiders own 18.51% of the company’s stock.

About Globus Medical

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.